|
The following poster was presented at the 2024 World Conference on Lung Cancer: EP.07D.03 A Quality Improvement Initiative to Address Biomarker Testing and Quality of Care Delivery for Early-Stage NSCLC at 3 Cancer Centers in the US Journal of Thoracic Oncology, October 2024, Volume 19, Issue 10, S548-S549 doi.org/10.1016/j.jtho.2024.09.1016  The following posters were presented at the 2024 ASCP Annual Meeting in Chicago:
Results of a quality improvement program to increase complete lung cancer biomarker testing rates by focusing on system, physician, and other factors associated with adverse health outcomes
Journal of Clinical Oncology 42, 2024 (suppl 16; abstr e23249) doi.org/10.1200/JCO.2024.42.16_suppl.e23249 Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study Journal of Clinical Oncology 42, 2024 (suppl 16; abstr 6079) ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.6079 Integrating electronic health records (EHRs) to facilitate cancer biomarker testing: Real-world implementation barriers and solutions Journal of Clinical Oncology 42, 2024 (suppl 16; abstr e13649) doi.org/10.1200/JCO.2024.42.16_suppl.e13649
EP12.02-10 Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative
Journal of Thoracic Oncology, Volume 18, Issue 11, S678 doi.org/10.1016/j.jtho.2023.09.1303 EP07.04-22 Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US Journal of Thoracic Oncology, Volume 18, Issue 11, S554 doi.org/10.1016/j.jtho.2023.09.1035 EP07.04 EARLY-STAGE NON-SMALL CELL LUNG CANCER - PROGRESS IN PATHOLOGY| VOLUME 18, ISSUE 11, SUPPLEMENT , S554, NOVEMBER 2023 EP12.02 METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY - FUSIONS| VOLUME 18, ISSUE 11, SUPPLEMENT , S678, NOVEMBER 2023 Key Considerations when Evaluating Whether to Establish a PD-L1 Laboratory Developed Test (LDT)
academic.oup.com/ajcp/article/160/Supplement_1/S90/7455442?login=false Poster presented at American Society for Clinical Pathology 2023 Hung Y, Liu X, Nam M, Rosa M, Saeed L, Schulte JJ, Zhang H, Zhang W, Chivukula M, Beumer K, Kelly M, Kim J, Lazure P, Murray S. Key Considerations when Evaluating Whether to Establish a PD-L1 Laboratory Developed Test (LDT). Am J Clin Pathol. 2023;160(Supplement_1):S90. Results of a quality improvement program to increase complete lung cancer biomarker testing rates.
ascopubs.org/doi/10.1200/OP.2023.19.11_suppl.57 Poster presented at ASCO Quality Care Symposium 2023 Heron DE, Blair J, Francis JE, Stoeppler-Biege K, Simpson L, Stapp J, Kim J. Results of a quality improvement program to increase complete lung cancer biomarker testing rates. JCO Oncol Pract. 2023;19(11_suppl):57-57. Key Considerations when Evaluating Whether to Establish a PD-L1 Laboratory Developed Test (LDT)
American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November 2023, Page S90 doi.org/10.1093/ajcp/aqad150.199 Disseminating Education about HER2-Low Breast Cancer through Twitter Chats and Tweetorials American Journal of Clinical Pathology, Volume 160, Issue Supplement_1, November 2023, Pages S97–S98 doi.org/10.1093/ajcp/aqad150.215 Challenges in Testing Across the HER2+ Breast Cancer Spectrum
This CME/CMLE-accredited, case-based microlearning activity from ASCP is designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum. Every few days, participants will be emailed or sent several questions through the Qstream app. Each question consists of an authentic patient case/scenario and an assessment question with 3-5 multiple-choice answers designed to help you make an appropriate diagnosis/recommendation. Visit ASCP’s Qstream site at ascp.qstream.com/ Sign up for a Qstream account. Enroll in the case-based microlearning series "Challenges in Testing Across the HER2+ Breast Cancer Spectrum."  Clinical Education Alliance (CCO, PCE, ProCE), in partnership with Q Synthesis LLC, invites outpatient medical practices in the United States to apply to join a national quality improvement (QI) program on obesity care.
pages.mycea.com/EVT_2023-Jan-Obesity_Change_Makers.html |
